IL Dong Pharmaceutical

At a glance

IL Dong Pharmaceutical filed 42 disclosures in the last 12 months, including 5 earnings, 1 insider, 1 5% holder and 1 m&a. The most recent key filing was on Jul 30.

Revenue for 2025 was ₩567B, down 7.8% on 2024. Operating margin was 3.4% against 2.1% a year earlier. Debt was 139% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩290B and operating profit of ₩11.2B.

The 2025 annual report lists 1,104 employees with an average tenure of 11 years and average pay of ₩79.7M, #379 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩228M each on average. It paid ₩200 per common share in cash dividends. 일동홀딩스(주) and related parties held 34.46% at year end.

From the 2025 annual report

Staff: 1,104 (739 men, 365 women), of whom 24 on fixed-term contracts. Total pay for the year: ₩86.2B. Directors and auditors: 8, paid ₩1.8B in total.

Dividends (common shares)

Largest shareholder

일동홀딩스(주) holds 30.52%; with 12 related parties the group holds 34.46% of common shares at year end (from 38.87% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary